BEI ZHANG

Ms. BEI ZHANG

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in China CDC Weekly
Verified
Journal Article
Open access
PDF file
XNXue Ni
Xue Ni
BZBEI ZHANG
BEI ZHANG
NXNing Xu
Ning Xu
XZXinying Zeng
Xinying Zeng
QWQiang Wang
Qiang Wang
CPChinese Center For Disease Control And Prevention The National Center For Chronic And Noncommunicable Disease Control And Prevention
Chinese Center For Disease Control And Prevention The National Center For Chronic And Noncommunicable Disease Control And Prevention
What is already known about this topic? The incidence of female lung cancer in China has been rising, whereas the incidence ratio among men and women is declining. The rising trend of female lung cancer is a prominent public health concern for China. What is added by this report? The joint secular trends distribution of the incidence, mortality, and years of life lost (YLLs) due to premature death of lung cancer in Chinese women demonstrated a certain regionality, which implied the risk factors for female lung cancer in China might be different by region. Common determinant risk factors may exist in regions sharing the same joint secular trends. What are the implications for public health practice? The secular trends and the regional pattern of the trends of female lung cancer in China suggested that the prevention and control of female lung cancer should be implemented with targeted regional interventions.

25 August 2021 in Environmental Science and Pollution Research
Verified
Journal Article
Closed access
PDF file
BZBEI ZHANG
BEI ZHANG
HSHui Sun
Hui Sun
QWQiang Wang
Qiang Wang

20 April 2026 in Microorganisms
Verified
Journal Article
Open access
PDF file
DODele Ogunremi
Dele Ogunremi
NDNaana Duah
Naana Duah
TTTianbi Tan
Tianbi Tan
BZBEI ZHANG
BEI ZHANG
LGLawrence Goodridge
Lawrence Goodridge
The effective control of foodborne salmonellosis relies on the rapid and reliable detection and identification of the pathogen. Reliable detection tools for identifying the most common Salmonella serovars should translate to a considerable alleviation of the health burden attributed to Salmonella. We have developed a PCR assay for the rapid identification of colonies of Salmonella enterica serovar Thompson, a common serovar. Genomic analyses of publicly available sequences of Salmonella Thompson revealed the presence of a unique, Thompson-specific fragment, which we have used to design a pair of oligonucleotides, STho-F and STho-R, for the PCR amplification of an 808 bp DNA fragment. Using crude DNA extracts, the 808 bp fragment was detected in 77 out of 78 isolates of S. Thompson (sensitivity = 98.7% n = 78 isolates) but not in any of the non-Salmonella organisms tested (n = 100; 100% specificity) nor in non-Thompson Salmonella serovars (n = 100; 100% specificity). The sensitivity (inclusivity) and specificity (exclusivity) indices of the PCR assay for S. Thompson met the standard regulatory requirements. The Thompson primer pair was compatible with other primers pairs in a multiplex PCR designed for three other common Salmonella serovars. Colonies belonging to the Enteritidis serovar (n = 100), Heidelberg serovar (n = 100), Typhimurium serovar (n = 100), and Thompson serovar (n = 77) were correctly designated, indicating excellent inclusivity and exclusivity scores for all four Salmonella serovars tested in a single multiplex PCR.

1 July 2021 in Cancer Research
Verified
Journal Article
Closed access
SWShengguang Wang
Shengguang Wang
BZBEI ZHANG
BEI ZHANG
Background: Genomic expression profiles have enabled the classification of lung adenocarcinoma (LUAD) into molecular sub-types and provide prognostic information, which have implications for the personalized treatment of LUAD beyond clinical and pathological features. Methods: Gene-expression profiling was performed on 459 patients in TCGA-LUAD(I-IIIa) for which RNA sequencing data and clinical covariates were available. A single-sample gene set enrichment analysis (ssGSEA) algorithm were used to quantified the levels of various hallmarks of cancer. And LASSO Cox regression model was used to screen robust prognostic biomarkers to identify the best set of survival-associated gene signatures in LUAD. Statistical analyses were performed using R version 3.4.4. Results: We identified glycolysis as the primary risk factor for survival(HR=0.55 [0.38-0.8], P<0.001)among various hallmarks of cancer in TCGA-LUAD. And glycolysis ssGESA scores were significantly elevated in patients who died during follow up (P<0.001). Kaplan-Meier analysis showed that patients with high ssGSEA scores of glycolysis exhibited worse OS ( HR=1.9,P= 0.001).Adjusted for stage,age,gender, our signature was an independent risk factor for overall survival in TCGA cohorts (HR=1.67[1.19-2.30],P= 0.003). We then apply the glycolysis -related gene signature to classify patients into the high risk group and the low risk group with the cutoff of median. In external independent cohorts, similar results were observed. In the validation cohort GEO31210, the multivariate Cox regression analysis showed that glycolysis -related gene signature exhibited an independent risk prediction for overall survival in 226 patients with stage I-II LUAD (HR=2.5 [1.11-5.5], P =0.025). Conclusions: By analyzing the gene-expression data with bioinformation approach, we developed and validated a risk prediction model with glycolysis -related expression scores in early stage LUAD, which have the potential to identify patients who could have better overall survival. Furthmore, our study confirmed that tumor glycolysis has wide-ranging effects, would become an attractive therapeutic target. Citation Format: Shengguang Wang, Zhang Bei. Development and validation of a glycolysis-related gene signature to predict overall survival in lung adenocarcinoma patients [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 664.